Cargando…

P858: EPIGENETIC REGULATION OF CD155 ON MULTIPLE MYELOMA CELLS INFLUENCES ANTI-TUMOR T-CELL CYTOTOXICITY

Detalles Bibliográficos
Autores principales:	Martinez-Verbo, L., Llinàs-Arias, P., Villanueva, L., García-Prieto, C. A., Piñeyro, D., Ferrer, G., Esteller, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430531/ http://dx.doi.org/10.1097/01.HS9.0000846312.91123.2f

Ejemplares similares

P822: EPIGENETIC REGULATION OF CD155 ON MULTIPLE MYELOMA CELLS INFLUENCES ANTI-TUMOR NOVEL IMMUNOTHERAPEUTIC APPROACHES
por: Martinez-Verbo, Laura, et al.
Publicado: (2023)

P858: FUNCTIONAL STUDIES IN MULTIPLE MYELOMA CELL LINESWITH OVEREXPRESSION OF NRAS Q61R MUTATION
por: Liotti, Romano, et al.
Publicado: (2023)

Epigenetic inactivation of tumour suppressor coding and non-coding genes in human cancer: an update
por: Llinàs-Arias, Pere, et al.
Publicado: (2017)

Epigenetic loss of the transfer RNA-modifying enzyme TYW2 induces ribosome frameshifts in colon cancer
por: Rosselló-Tortella, Margalida, et al.
Publicado: (2020)

858. Inter-rater Reliability of Hand Hygiene Observers with an Electronic Monitoring System
por: Bailey, Pamela, et al.
Publicado: (2020)

Remodeling of the m(6)A RNA landscape in the conversion of acute lymphoblastic leukemia cells to macrophages
por: Bueno-Costa, Alberto, et al.
Publicado: (2022)

P828: EFFECT OF ANTI-CD38 MONOCLONAL ANTIBODIES ON THE INTERACTION OF MYELOMA CELLS WITH BONE MARROW STROMAL CELLS
por: Lienhart, Malgorzata, et al.
Publicado: (2023)

P05 ACETYL SALICYLIC ACID INDUCES POLARIZATION OF MACROPHAGES AND CYTOTOXICITY ON MYELOMA CELLS IN VITRO
por: Gonulkirmaz, N., et al.
Publicado: (2023)

DNA methylation-associated dysregulation of transfer RNA expression in human cancer
por: Rosselló-Tortella, Margalida, et al.
Publicado: (2022)

Genetics and epigenetics of leukemia and lymphoma: from knowledge to applications, meeting report of the Josep Carreras Leukaemia Research Institute
por: Parra, Maribel, et al.
Publicado: (2020)

P861: SIALOFUCOSYLATED STRUCTURES ENABLE PLATELET BINDING TO MYELOMA CELLS CONFERRING PROTECTION FROM NK-MEDIATED CYTOTOXICITY
por: Natoni, A., et al.
Publicado: (2022)

858. Impact of Using an Order Set on PrEP Prescribing and Laboratory Monitoring in Primary Care
por: Dao, Linda T, et al.
Publicado: (2021)

P808: CONTROLLED FRATRICIDE TO AUGMENT ANTI-MYELOMA REACTIVITY OF SLAMF7 AND CD38 CAR T CELLS
por: Konetzki, Verena, et al.
Publicado: (2023)

The DNA methylation landscape of hematological malignancies: an update
por: Blecua, Pedro, et al.
Publicado: (2020)

PVR (CD155) Expression as a Potential Prognostic Marker in Multiple Myeloma
por: Lee, Byung-Hyun, et al.
Publicado: (2022)

P58 LOW CD38 EXPRESSION BY PLASMA CELLS IN EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA PATIENTS
por: Notarfranchi, L., et al.
Publicado: (2023)

P802: CD70/CD27 SIGNALING PROMOTES THE EXPANSION OF CLONAL PLASMA CELL SUBSETS IN MULTIPLE MYELOMA
por: Forster, Stefan, et al.
Publicado: (2023)

Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies
por: Garcia-Prieto, Carlos A, et al.
Publicado: (2021)

P816: PHARMACODYNAMIC ACTIVITY OF GEN3014 (HEXABODY-CD38) IN PATIENTS WITH MULTIPLE MYELOMA SUPPORTS ENHANCED COMPLEMENT DEPENDENT CYTOTOXICITY OF GEN3014 COMPARED TO DARATUMUMAB
por: Hiemstra, Ida H., et al.
Publicado: (2023)

Pet imaging of cytotoxic human T cells using an 89Zr-labeled anti-CD8 minibody
por: Olafsen, Tove, et al.
Publicado: (2015)

Hdac3 is an epigenetic inhibitor of the cytotoxicity program in CD8 T cells
por: Tay, Rong En, et al.
Publicado: (2020)

P842: NOVEL MULTIFUNCTIONAL TETRAVALENT CD38 NKP46 FLEX-NK ENGAGERS ACTIVELY TARGET AND KILL MULTIPLE MYELOMA CELLS
por: Lin, L., et al.
Publicado: (2022)

miR-155 harnesses Phf19 to potentiate cancer immunotherapy through epigenetic reprogramming of CD8(+) T cell fate
por: Ji, Yun, et al.
Publicado: (2019)

Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
por: Drent, Esther, et al.
Publicado: (2015)

Correction: Hdac3 is an epigenetic inhibitor of the cytotoxicity program in CD8 T cells
por: Tay, Rong En, et al.
Publicado: (2020)

YM155 enhances the cytotoxic activity of etoposide against canine osteosarcoma cells
por: ONG, Siew Mei, et al.
Publicado: (2019)

Epigenetic regulation of CD1d-mediated antigen presentation in B cell lymphoma
por: Tiper, Irina, et al.
Publicado: (2014)

P859: ANTI-CD38 NANOBODY JK36 ALLOWS RELIABLE MRD DETECTION IN DARATUMUMAB TREATED MULTIPLE MYELOMA PATIENTS
por: Meseguer Martinez, E., et al.
Publicado: (2022)

P25 EFFECT OF DARATUMUMAB ON STEM CELL YIELDS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: REPORT FROM THE MULTIPLE MYELOMA LAZIO GROUP
por: Fazio, F., et al.
Publicado: (2023)

Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth
por: Ma, Xun, et al.
Publicado: (2018)

P32 MAJESTEC-1: CORRELATIVE ANALYSES OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: van de Donk, N., et al.
Publicado: (2023)

The potential role of HIV-specific CD38-/HLA-DR+ CD8+ T cells in viral suppressive activity and cytotoxicity in HIV controllers
por: Hua, Stéphane, et al.
Publicado: (2014)

P800: CHARACTERIZATION OF REGULATORY T CELLS IN PATIENTS WITH MULTIPLE MYELOMA
por: Kim, Sojeong, et al.
Publicado: (2023)

P965: STEM-CELL MOBILIZATION WITH CYCLOPHOSPHAMIDE 4 G/M2 ALLOWS COLLECTION OF HIGH NUMBERS OF CD34+ CELLS AFTER DARA-VTD INDUCTION FOR MULTIPLE MYELOMA
por: Perini, Tommaso, et al.
Publicado: (2023)

P925: PHASE 1 TRIAL OF ANTI-CD38 MONOCLONAL ANTIBODY CM313 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA OR LYMPHOMA
por: Chen, Wenming, et al.
Publicado: (2023)

Enrichment of KIR+CD57+ highly cytotoxic NK cells in sentinel lymph nodes of melanoma patients
por: Ali, Talib Hassan, et al.
Publicado: (2014)

Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation
por: Fionda, Cinzia, et al.
Publicado: (2015)

CD155/TIGIT signalling plays a vital role in the regulation of bone marrow mesenchymal stem cell–induced natural killer–cell exhaustion in multiple myeloma
por: Liu, Zhao‐Yun, et al.
Publicado: (2022)

P815: HIGH VALENCY OF IGM-2644, A CD38XCD3 IGM BISPECIFIC T CELL ENGAGER, DISPLACES DARATUMUMAB BINDING AND INDUCES POTENT MULTIPLE MYELOMA CELL KILLING
por: Hart, Kevin C., et al.
Publicado: (2023)

A155 ASEPTIC ABSCESS SYNDROME IN INFLAMMATORY BOWEL DISEASE: A CASE REPORT
por: Tam, L, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bhg6srj2v9i4t83k9kfjldbars